SCHEMBL2214929

SCHEMBL2214929

Cc1cccc2c1CCC2NC1=NCCN1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1D P28221 2/20 0.50
ADRA2A P08913 7/20 0.46
ADRA1A P35348 6/20 0.46
ADRA2C P18825 5/20 0.46
ADRA2B P18089 4/20 0.46
ADRA1D P25100 4/20 0.46
ADRA1B P35368 4/20 0.46
TRPV1 Q8NER1 1/20 0.40
LMNA P02545 3/20 0.38
CYP2D6 P10635 2/20 0.38
CYP2C19 P33261 2/20 0.38
NISCH Q9Y2I1 2/20 0.38
MEN1 O00255 1/20 0.38
SLC22A1 O15245 1/20 0.38
SLC22A3 O75751 1/20 0.38
HTR1A P08908 1/20 0.38
CYP2C9 P11712 1/20 0.38
HRH2 P25021 1/20 0.38
OPRK1 P41145 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12437177 1.00 HTR1D (0.50) HTR1DADRA2AADRA1AADRA2CADRA2B
SCHEMBL12437176 1.00 HTR1D (0.50) HTR1DADRA2AADRA1AADRA2CADRA2B
SCHEMBL2215126 0.84 GID4 (0.39) HTR1DADRA2AADRA1AADRA2CADRA2B
SCHEMBL4783949 0.80 TAS1R3 (0.44) ADRA2AADRA1AMEN1KMT2A
SCHEMBL2215206 0.78 ADRA1A (0.49) HTR1DADRA2AADRA1AADRA2CADRA2B
SCHEMBL12437174 0.78 ADRA1A (0.49) HTR1DADRA2AADRA1AADRA2CADRA2B
Acetic Acid SCHEMBL4808426 0.77 TAS1R3 (0.44) ADRA2AADRA1AMEN1KMT2A
SCHEMBL11903742 0.76 LMNA (0.57) ADRA2AADRA1AADRA2CADRA2BADRA1D
SCHEMBL2216724 0.75 UGT2B17 (0.44) HTR1DADRA2AADRA1AADRA2CADRA2B
SCHEMBL4808439 0.75 CA1 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101855213-B Therapeutic compounds ALLERGAN INC 2014-09-10 CN disclosed
US-20110178143-A1 THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2011-07-21 US disclosed
US-20110178143-A1 THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2011-07-21 US disclosed
US-20110178143-A1 THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2011-07-21 US disclosed
CN-101855213-A Therapeutic compounds ALLERGAN INC 2010-10-06 CN disclosed
EP-2188261-A1 THERAPEUTIC COMPOUNDS Allergan, Inc. (US) 2010-05-26 EP disclosed
WO-2009023757-A1 THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2009-02-19 WO disclosed
WO-2009023757-A1 THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2009-02-19 WO disclosed
WO-2008115141-A1 4, 5-DIHYDRO-1,3-THIAZOL-2-AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF RESPIRATORY, CARDIOVASCULAR, NEUROLOGICAL OR GASTROINTESTINAL DISORDERS ALBIREO AB (SE) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178143-A1 THERAPEUTIC COMPOUNDS GOT2, GOT1, ANXA5 HTR1D 3687/4885ADRA2A 1550/4885ADRA1A 1706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.